Biofrontera Inc. (BFRI)

Compare

0.7874

-0.0136

(-1.70%)

At close: April 3 at 4:00:00 PM EDT

Biofrontera Full Year 2024 Earnings: Misses Expectations

Biofrontera ( NASDAQ:BFRI ) Full Year 2024 Results Key Financial Results Revenue: US$37.3m (up 9.5% from FY 2023). Net...

Simply Wall St. 12 days ago

BFRI
-1.70%
BFRIW
Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ...

Biofrontera Inc (BFRI) reports significant revenue growth and strategic advancements, yet faces ongoing net losses and financial hurdles.

GuruFocus.com 13 days ago

BFRIW
Q4 2024 Biofrontera Inc Earnings Call

Q4 2024 Biofrontera Inc Earnings Call

Thomson Reuters StreetEvents 13 days ago

BFRIW
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2024. Highlights from 2024 and subsequent weeks include: Reported record total revenues of $37.3 million for 2024, reflecting a 9.5% increase from $3

GlobeNewswire 14 days ago

BFRI
-1.70%
BFRIW
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremitiesProtocol involves one or two PDT treatments using 1-3 tubes of Ameluz® or vehicle gel over a surface area of up to 240 cm2Treatment phase expected to be complete by Q3 2025 WOBURN, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today a

GlobeNewswire 16 days ago

BFRI
-1.70%
BFRIW
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time. Conference Ca

GlobeNewswire 23 days ago

BFRI
-1.70%
BFRIW
When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit?

Biofrontera Inc. ( NASDAQ:BFRI ) is possibly approaching a major achievement in its business, so we would like to shine...

Simply Wall St. last month

BFRI
-1.70%
BFRIW
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up will be included in FDA submission, expected in Q3 2025.Biofrontera announced highly statistically significant results for all primary and secondary endpoints (p <0.0001) in October 2024.BCC, of which sBCC is a subgroup, is the most common skin cancer in the US with more than 3 million cases each year1. WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera”

GlobeNewswire 2 months ago

BFRI
-1.70%
BFRIW
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US market since launch.The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalp.Biofrontera’s RhodoLED XL and BF-RhodoLED lamps deliver red light energy using long-lasting light-emitting diode (LED) arrays. WOBURN, Mass., Dec

GlobeNewswire 3 months ago

BFRI
-1.70%
BFRIW
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced it will ...

ACCESS Newswire 3 months ago

BFRI
-1.70%
BFRIW
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the completion of a private placement of a $4.2 million senior secured convertible note (the “Note”) with its principal shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s asse

GlobeNewswire 4 months ago

BFRI
-1.70%
BFRIW
Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...

Biofrontera Inc (BFRI) reports significant clinical progress and cost reductions, despite weather-related shipment delays impacting Q3 revenue.

GuruFocus.com 4 months ago

BFRIW
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -17.81% and 18.15%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

BFRIW
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton. ●Total revenues for the first 9 months were $24.8 million, an increase of $1.3 million, or 5.6% as compared to the same period last year. Without the impact of Hurricane Milton delaying shipments, the increase would have been 12%. ●Ameluz® achieved record volume in September 2024. ●Organization continues to pru

GlobeNewswire 4 months ago

BFRI
-1.70%
BFRIW
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for ...

ACCESS Newswire 4 months ago

BFRI
-1.70%
BFRIW
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant p<0.0001Correlates to data seen in Europe where sBCC is already incorporated in the Summary of Product Characteristics.BCC is the most common skin cancer in the US, with more than 3 million cases each year1. WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing

GlobeNewswire 4 months ago

BFRI
-1.70%
BFRIW
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc

Rosalind Advisors, Inc. (Trades, Portfolio), a notable investment firm, recently adjusted its investment in Biofrontera Inc (NASDAQ:BFRI), a biopharmaceutical company based in the USA. On September 30, 2024, the firm executed a reduction in its holdings by 8,771 shares, resulting in a new total of 495,490 shares.

GuruFocus.com 5 months ago

BFRIW
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

First Phase 3 PDT study in patients with sBCC in the United States.Rigorous dual endpoints requiring complete clinical and cytological clearance of malignant lesions.Data now being analyzed, interim results expected November 2024.BCC is the most common skin cancer in the US with more than 3 million cases each year1. WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and com

GlobeNewswire 5 months ago

BFRI
-1.70%
BFRIW
Biofrontera Inc (BFRI) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Biofrontera Inc (BFRI) reports a 34% revenue increase and significant expense reductions, setting the stage for future profitability.

GuruFocus.com 5 months ago

BFRIW
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz®-PDT using the BF-RhodoLED or the RhodoLED XL lampSupplemental New Drug Application (sNDA) supported by two Phase 1 safety studiesAK is the second most common diagnosis made by dermatologists in the United States1An estimated 13 million treatments given each year for AK in the US2 WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a bi

GlobeNewswire 5 months ago

BFRI
-1.70%
BFRIW

Performance Overview

Return	BFRI	S&P 500 (^GSPC)
YTD	-27.76%	-8.25%
1-Year	-56.26%	+3.55%
3-Year	-98.88%	+18.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biofrontera Inc. (BFRI)

Biofrontera Full Year 2024 Earnings: Misses Expectations

Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ...

Q4 2024 Biofrontera Inc Earnings Call

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit?

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc (BFRI) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Performance Overview